Login / Signup

Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA₂ in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome.

Hyo Sun LeeChang Hee JungSung Rae KimHak Chul JangCheol Young Parknull null
Published in: Endocrinology and metabolism (Seoul, Korea) (2016)
Pitavastatin treatment and LSM significantly improved lipid profiles, ApoB-100/A1 ratio, and reduced ApoB-48 levels in the higher mean baseline value group of ApoB-48, but did not significantly alter the Lp-PLA₂ levels.
Keyphrases
  • metabolic syndrome
  • uric acid
  • combination therapy
  • cardiovascular risk factors
  • replacement therapy
  • double blind